Iv%252525252525252525252525252520dexamethasone

# IV Dexamethasone ## Overview Dexamethasone is a potent, long-acting synthetic glucocorticoid with minimal mineralocorticoid activity. It provides profound anti-inflammatory and immunosuppressive effects. ## Primary Indications * Cerebral edema (associated with brain tumors, neurosurgery) * Severe allergic reactions or anaphylaxis (adjunctive) * Acute exacerbations of asthma or COPD * Anti-emetic therapy (chemotherapy-induced) * Severe COVID-19 (requiring supplemental oxygen) * Bacterial meningitis (adjunctive, administered with or before first antibiotic dose) ## Adult Dosing * **Cerebral Edema:** Initial 10 mg IV, followed by 4 mg IV every 6 hours. * **Anti-emetic:** 8–20 mg IV once prior to chemotherapy. * **COVID-19:** 6 mg IV once daily for up to 10 days. * **Bacterial Meningitis:** 10 mg IV every 6 hours for 4 days. * **Allergic Reactions:** 4–20 mg IV single dose or repeated as needed. ## Pediatric Dosing * **Cerebral Edema:** Loading dose 1–2 mg/kg/dose, followed by 1–1.5 mg/kg/day divided every 4–6 hours (max dose often protocol-dependent). * **Bacterial Meningitis:** 0.15 mg/kg/dose every 6 hours for 4 days (initiate with or prior to antibiotics). * **Anti-emetic:** 0.1–0.5 mg/kg/dose (max 10–20 mg) prior to chemotherapy. * **Extubation/Airway Edema:** 0.25–0.5 mg/kg/dose every 6 hours; start 12–24 hours prior to extubation. ## Dose Adjustments * **Hepatic Impairment:** Clearance may be decreased in severe liver disease; monitor for systemic toxicity. * **Renal Impairment:** No specific adjustment required. * **Chronic Use:** Taper gradually to avoid adrenal insufficiency if used for >7–14 days. ## Contraindications * Systemic fungal infections. * Hypersensitivity to dexamethasone or product components. * Administration of live or live-attenuated vaccines in immunocompromised patients. ## Adverse Effects * **Common:** Hyperglycemia, hypertension, insomnia, mood changes, fluid retention. * **Serious:** GI bleeding/ulceration, secondary infection risk, adrenal suppression, posterior subcapsular cataracts, osteoporosis (with chronic use). ## Key Drug Interactions * **CYP3A4 Inducers (e.g., phenytoin, phenobarbital, rifampin):** Decreased dexamethasone levels; may require dose increase. * **CYP3A4 Inhibitors (e.g., ritonavir, ketoconazole):** Increased dexamethasone levels; monitor for toxicity. * **NSAIDs/Aspirin:** Increased risk of GI ulceration. * **Warfarin:** Variable effects on INR; monitor closely when initiating or withdrawing steroids. * **Diuretics:** Increased risk of hypokalemia. ## Monitoring * **Routine:** Blood glucose (especially in diabetics), blood pressure, electrolyte status (potassium). * **Long-term/High-dose:** Signs of GI bleeding (occult blood tests), psychological status, signs of latent infection, weight gain. ## Clinical Pearls * **Rapid Administration:** IV bolus is generally safe, but rapid injection can cause a transient "perineal burning" sensation; infuse over 1-2 minutes to mitigate. * **Bacterial Meningitis:** Effectiveness is highly dependent on timing; if the first dose of antibiotics is already administered, dexamethasone effect is likely reduced. * **Local Protocols:** Institutional protocols for COVID-19 management or chemotherapy anti-emetic regimens may vary significantly; always consult local guidelines prior to administration. *** *Disclaimer: This information is for educational purposes only and does not constitute medical advice. Medication prescribing and dosing should always be verified against the most current institutional guidelines, drug package inserts, and clinical resources (e.g., Lexicomp, Micromedex) to account for patient-specific variables.*